{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:28:53Z","timestamp":1770964133976,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clcc.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:22:16Z","timestamp":1691547736000},"page":"442-449.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases"],"prefix":"10.1016","volume":"22","author":[{"given":"Ofer","family":"Margalit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivan","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilanit","family":"Redinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Halparin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Honig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoz","family":"Ben-Ayun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Shacham-Shmueli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naama","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza","family":"Ackerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eytan","family":"Ben-Ami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeriya","family":"Semenisty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Purim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirit","family":"Yarom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Boursi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvi","family":"Symon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Art M.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9959-2485","authenticated-orcid":false,"given":"Yaacov R.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clcc.2023.08.004_bib0001","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clcc.2023.08.004_bib0002","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clcc.2023.08.004_bib0003","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2023.08.004_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41590-017-0012-z","article-title":"Diversification of human plasmacytoid predendritic cells in response to a single stimulus","volume":"19","author":"Alculumbre","year":"2018","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.clcc.2023.08.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.clcc.2023.08.004_bib0006","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2023.08.004_bib0007","first-page":"A999","article-title":"950\u2005final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod \u00b1 pembrolizumab in patients with PD-1 blockade\u2013refractory melanoma","volume":"9","author":"Kirkwood","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clcc.2023.08.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100983","article-title":"Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity","volume":"14","author":"Younes","year":"2021","journal-title":"Transl Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2023.08.004_bib0009","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nature Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2023.08.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clcc.2023.08.004_bib0011","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2022.04.453","article-title":"LBA O-9 Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer","volume":"33","author":"Bullock","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2023.08.004_bib0012","doi-asserted-by":"crossref","first-page":"S684","DOI":"10.1016\/j.annonc.2022.07.458","article-title":"320MO a phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)","volume":"33","author":"Fakih","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2023.08.004_bib0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2023.08.004_bib0014","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.08.034","article-title":"High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy","volume":"177","author":"Dercle","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clcc.2023.08.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association between survival and metastatic site in mismatch repair\u2013deficient metastatic colorectal cancer treated with first-line pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"52","key":"10.1016\/j.clcc.2023.08.004_bib0016","doi-asserted-by":"crossref","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.clcc.2023.08.004_bib0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.clcc.2023.08.004_bib0018","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2023.08.004_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2023.41.4_suppl.141","article-title":"Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study","volume":"41","author":"Seligmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2023.08.004_bib0020","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.4049\/jimmunol.170.8.4061","article-title":"CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha","volume":"170","author":"Blackwell","year":"2003","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"3","key":"10.1016\/j.clcc.2023.08.004_bib0021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2567.2009.03134.x","article-title":"Tumour-derived prostaglandin E2 and transforming growth factor-\u03b2 synergize to inhibit plasmacytoid dendritic cell-derived interferon-\u03b1","volume":"128","author":"Bekeredjian-Ding","year":"2009","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.clcc.2023.08.004_bib0022","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ijc.28072","article-title":"Breast cancer-derived transforming growth factor-\u03b2 and tumor necrosis factor-\u03b1 compromise interferon-\u03b1 production by tumor-associated plasmacytoid dendritic cells","volume":"133","author":"Sisirak","year":"2013","journal-title":"Int J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:25Z","timestamp":1761520165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002823000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1533002823000774"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.08.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}